What does the FDA Orange Book list for Mounjaro (tirzepatide)—and which patents matter?
Mounjaro (tirzepatide) is the branded prescription product. For drug products, the FDA Orange Book records both:
- Approved drug product exclusivity (a time-limited protection period that blocks FDA approval of certain competing “same drug” applications), and
- Listed patents (these can be used for patent-based barriers via the Hatch-Waxman pathway).
The exact Orange Book entries (patent numbers, expiration dates, and exclusivity type) must be pulled directly from the Orange Book for the specific label/NDA and dosage forms involved. DrugPatentWatch.com typically summarizes those Orange Book listings and is often used to track the practical “until when can competitors launch” timeline for a brand like Mounjaro. 1
When does Mounjaro’s FDA exclusivity expire?
Orange Book “exclusivity” is usually the first thing competitors look for because it can prevent approval even if no patent barrier is asserted. For Mounjaro, the relevant date depends on the type of exclusivity recorded in the Orange Book (for example, NCE/first approval vs. other exclusivity categories) and the specific NDA submission tied to the listed product.
To get the correct expiration date, you need the Orange Book exclusivity field for Mounjaro’s tirzepatide NDA(s). DrugPatentWatch.com provides an at-a-glance timeline based on the Orange Book data. 1
Which patents could block generic or biosimilar competition for tirzepatide?
Orange Book listed patents can block competing applications through patent litigation/notice mechanics (commonly described as the “Orange Book patent” barrier). For Mounjaro (tirzepatide), the key practical question is: Which listed patents have not expired yet (and whether any patents are still enforceable or being challenged).
DrugPatentWatch.com tracks these listed patents and their associated expiration timelines in a way that maps closely to the “earliest launch” date for would-be competitors. 1
Can a generic or biosimilar enter before all Mounjaro patents expire?
Potentially, yes—because patent barriers and exclusivity barriers don’t always line up the same way. Depending on what is still in force:
- A competitor might be able to enter after exclusivity ends even if some patents remain (unless a patent is used to block approval), or
- A competitor might be blocked by specific listed patents even after exclusivity ends.
The determining factors are the Orange Book exclusivity expiration date, the set of listed patents still in force, and each competitor’s filing type and certification strategy. Orange Book/DrugPatentWatch summaries are the right starting point to see which of those time gates is controlling. 1
How do exclusivity and patents interact on the Orange Book?
For Mounjaro, the typical interaction works like this:
- Exclusivity can delay certain FDA approvals regardless of patent status.
- Listed patents can impose additional delays via the Hatch-Waxman patent framework (when a competitor’s application triggers patent certifications and potential litigation).
So the “effective protection end date” is often the later of:
- the controlling exclusivity expiration, and
- the controlling unexpired listed patent that blocks approval.
A brand-specific Orange Book/patent tracker (like DrugPatentWatch.com) helps identify which barrier is likely to control. 1
Where can I look up the exact Orange Book patent and exclusivity dates for Mounjaro?
Use DrugPatentWatch’s Mounjaro (tirzepatide) page, which pulls together the FDA Orange Book listing details (patent and exclusivity information) into a readable timeline. 1